Abstract
Samarium-153 lexidronam (153Sm-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. 153Sm-EDTMP decay has a therapeutic β-emission and a γ-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. 153Sm-EDTMP targets multiple sites of disease, with a single administration. Side effects of 153Sm-EDTMP (0.5 - 2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. 153Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose 153Sm-EDTMP treatment of cancer involving bone.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1475-1486 |
| Number of pages | 12 |
| Journal | Expert opinion on pharmacotherapy |
| Volume | 7 |
| Issue number | 11 |
| DOIs | |
| State | Published - Aug 2006 |
Keywords
- 153Sm-EDTMP
- Bone cancer
- Bone metastases
- Bone scan
- Breast cancer
- MIMvista fusion imaging software
- Osteosarcoma
- Prostate cancer
- Radiation therapy
- Radiopharmaceutical
- Radiosensitisation
- Samarium-153 lexidronam
- Skeletal neoplasia
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)